On the recordJanuary 8, 2018
I appreciate that you say that it is too high. Yet in that position, with this system, you doubled the price.
Source
congress.govEditor's note · Context
Stabenow criticizes Azar for increasing insulin prices while acknowledging they are too high.
Share
More from Debbie Stabenow
Dec 2, 2024
if there is no further business to come before the Senate, I ask that it stand adjourned under the previous order. There being no objection, the Senate, at 7:45 p.m., adjourned until Tuesday, December 3, 2024, at 12 noon…
Nov 18, 2024
There is no question. And we also have extensive evidence that when a bill is put forward on the floor that cuts the nutrition title, it never passes--2012 in the House, 2018 in the House. When Republican colleagues only put a bill on the…
Other voices in this conversation
